WEBINARS AND EVENTS Explore targeted therapies and management options for gastrointestinal cancer patients based on germline and genomic findings. Speakers: Howard McLeod PharmD, FASCO, FCCP, Center for Precision Medicine, Utah Tech University Lincoln Nadauld MD, PhD, GI Medical Oncology, Intermountain Health Darshil Shah MD, MPH, Director, Gastrointestinal Oncology, Ironwood Cancer & Research Center Porscha Johnson Williams PharmD, CPGx, Northside Hospital Olumide Gbolahan MBBS, Gastrointestinal Oncology, Emory University Date: 05/15/2025 Duration: 1 hour CEU: No Our first session of our quarterly Molecular Tumor Board, held in partnership with Clarified Health. This first session will focus on gastrointestinal cancer, providing comprehensive insights from tumor genomic profiling and germline results. We will discuss all critical biomarker results necessary for an informed discussion guiding treatment decisions. State-of-the-art and evidence-based assessment of Myriad Oncology’s tests and results Summarized, and de-identified, patient cases focusing on germline and tumor genomic landscapes Discussion of hereditary implications of genomic findings Prioritization of targeted therapy options based on genomic findings Hear from our speakers Howard McLeod PharmD, FASCO, FCCP, Center for Precision Medicine, Utah Tech University Lincoln Nadauld MD, PhD, GI Medical Oncology, Intermountain Health Darshil Shah MD, MPH, Director, Gastrointestinal Oncology, Ironwood Cancer & Research Center Porscha Johnson Williams PharmD, CPGx, Northside Hospital Olumide Gbolahan MBBS, Gastrointestinal Oncology, Emory University